---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043066"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:32:39.808645+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ZyVersa shareholders approve 150,000-share equity plan increase and up to 478,600 warrant shares

## Summary
- Elected Min Chul Park, Ph.D. as Class II director with 183,493 votes for, 13,425 withheld.
- Ratified Marcum LLP as independent auditor for FY2024 with 433,670 votes for.
- Approved amendment to 2022 Omnibus Equity Incentive Plan, increasing shares reserved by 150,000 to 181,795.
- Approved issuance of up to 478,600 shares upon exercise of certain warrants under Nasdaq Listing Rule 5635(d).
- Quorum of approx. 43% of outstanding shares (1,074,196 shares) was represented at the meeting.

## SEC filing metadata
- accession: 0001493152-24-043066
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315224043066/0001493152-24-043066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315224043066/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043066
- JSON: https://secwatch.observer/filing/0001493152-24-043066.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.